Evaluation of nanoencapsulated verteporfin's cytotoxicity using a microfluidic system

Journal of Pharmaceutical and Biomedical Analysis

Volumn 127, Issue , 2016, Pages 39-48

  Tokarska, Katarzyna ^a   Bułka, Magdalena ^a   Bazylińska, Urszula ^b   Jastrzębska, Elżbieta ^a   Chudy, Michał ^a   Dybko, Artur ^a   Wilk, Kazimiera A ^b   Brzózka, Zbigniew ^a  

^a WARSAW UNIVERSITY OF TECHNOLOGY   (Poland)

^b WROCLAW UNIVERSITY OF TECHNOLOGY   (Poland)

Author keywords

Cytotoxicity; Lab on a chip; Nanoencapsulated photosensitizers; Photodynamic therapy; Verteporfin

Indexed keywords

NANOCAPSULE; NANOCARRIER; PHOTOSENSITIZING AGENT; POLYELECTROLYTE; VERTEPORFIN; NANOMATERIAL; PORPHYRIN;

ARTICLE; CELL CULTURE; CELL GROWTH; CELL TRANSPORT; CELLULAR DISTRIBUTION; COCULTURE; CYTOTOXICITY; HUMAN; HUMAN CELL; IN VIVO STUDY; INTERNALIZATION; MICROFLUIDICS; MIXED CELL CULTURE; MOLECULAR STABILITY; MONOCULTURE; NANOENCAPSULATION; PHOTODYNAMIC THERAPY; PHOTON CORRELATION SPECTROSCOPY; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; A-549 CELL LINE; CELL SURVIVAL; CHEMISTRY; CYTOLOGY; DEVICES; DRUG EFFECTS; DRUG FORMULATION; LAB ON A CHIP; LUNG; MICROFLUIDIC ANALYSIS; PROCEDURES;

A549 CELLS; CELL SURVIVAL; DRUG COMPOUNDING; HUMANS; LAB-ON-A-CHIP DEVICES; LUNG; MICROFLUIDIC ANALYTICAL TECHNIQUES; NANOSTRUCTURES; PHOTOSENSITIZING AGENTS; PORPHYRINS;

EID: 84961231068     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2016.02.052     Document Type: Article

References (38)

1. [1] Kryman, M.W., Davies, S.K., Linder, M.K., Ohulchanskyy, T.Y., Detty, M.R., Selenorhodamine photosensitizers with the Texas-red core for photodynamic therapy of cancer cells. Bioorg. Med. Chem. 23 (2015), 4501–4507.
2. [2] Park, J.H., Ban, S.J., Ahmed, T., Choi, H.S., Yoon, H.E., Yoon, J.H., Choi, H.K., Development of DH-I-180-3 loaded lipid nanoparticle for photodynamic therapy. Int. J. Pharm. 491 (2015), 393–401.
3. [3] Samkoe, K.S., Fecica, M.S., Goyan, R.L., Buchholz, J.L., Campbell, C., Kelly, N.M., Cramb, D.T., Photobleaching kinetics of verteporfin and lemuteporfin in cells and optically trapped multilamellar vesicles using two-photon excitation. Photochem. Photobiol. Sci. 87 (2011), 853–861.
4. [4] Juzeniene, A., Moan, J., The history of PDT in Norway; Part one: identification of basic mechanisms of general PDT. Photodiag. Photodyn. Ther. 4 (2007), 3–11.
5. [5] Nakai, Y., Tatsumi, Y., Miyake, M., Anai, S., Kuwada, M., Onishi, S., Chihara, Y., Tanaka, N., Hirao, Y., Fujimoto, K., Expression of ferrochelatase has a strong correlation in protoporphyrin IX accumulation with photodynamic detection of bladder cancer. Photodiag. Photodyn. Ther., 2015, 10.1016/j.pdpdt.2015.07.174.
6. [6] Fukuhara, H., Inoue, K., Kurabayashi, A., Furihata, M., Fujita, H., Utsumi, K., Sasaki, J., Shuin, T., The inhibition of ferrochelatase enhances 5-aminolevulinic acid-based photodynamic action for prostate cancer. Photodiag. Photodyn. Ther. 10 (2013), 399–409.
7. [7] Weijer, R., Broekgaarden, M., Kos, M., van Vught, R., Rauws, E.A.J., Breukink, E., van Gulik, T.M., Storm, G., Heger, M., Enhancing photodynamic therapy of refractory solid cancers: combining second-generation photosensitizers with multi-targeted liposomal delivery. J. Photochem. Photobiol. C 23 (2015), 103–131.
8. [8] Nowak-Sliwinska, P., Karocki, A., Elas, M., Pawlak, A., Stochel, G., Urbanska, K., Verteporfin, photofrin II, and merocyanine 540 as PDT photosensitizers against melanoma cells. Biochem. Biophys. Res. Commun. 349 (2006), 549–555.
9. [9] Richter, A.M., Waterfield, E., Jain, A.K., Allison, B., Sternberg, E.D., Dolphin, D., Levy, J.G., Photosensitizing potency of structural analogues of benzoporphyrin derivative (BPD) in a mouse tumor model. Br. J. Cancer 63 (1991), 87–93.
10. [10] Sibrian-Vazquez, M., Jensen, T.J., Grac, M., Vicente, H., Synthesis and cellular studies of PEG-functionalized meso-tetraphenylporphyrins. J. Photochem. Photobiol. B: Biol. 86 (2007), 9–21.
11. [11] Daglar, B., Ozgur, E., Corman, M.E., Uzun, L., Dermiel, G.B., Polymeric nanocarriers for expected nanomedicine: current challenges and future prospects. RSC Adv. 4 (2014), 48639–48659.
12. [12] Bazylińska, U., Pietkiewicz, J., Saczko, J., Nattich-Rak, M., Rossowska, J., Garbiec, A., Wilk, K.A., Nanoemulsion-templated multilayer nanocapsules for cyanine-type photosensitizer delivery to human breast carcinoma cells. Eur. J. Pharm. Sci. 47 (2012), 406–420.
13. [13] Bazylińska, U., Drozdek, S., Nyk, M., Kulbacka, J., Samoć, M., Wilk, K.A., Core/shell quantum dots encapsulated in biocompatible oil-core nanocarriers as two-photon fluorescent markers for bioimaging. Langmuir 30 (2014), 14931–14943.
14. [14] Szczepanowicz, K., Bazylińska, U., Pietkiewicz, J., Szyk-Warszyńska, L., Wilk, K.A., Warszyński, P., Biocompatible long-sustained release oil-core polyelectrolyte nanocarriers: from controlling physical state and stability to biological impact. Adv. Colloid Interface Sci. 222 (2015), 678–691.
15. [15] Wu, M.H., Huangb, S.B., Lee, G.B., Microfluidic cell culture systems for drug research. Lab Chip 10 (2010), 939–956.
16. [16] El-Ali, J., Sorger, P.K., Jensen, K.F., Cells on chips. Nature 442 (2006), 403–411.
17. [17] Halldorsson, S., Lucumi, E., Gómez-Sjöberg, R., Fleming, R.M.T., Advantages and challenges of microfluidic cell culture in polydimethylsiloxane devices. Biosens. Bioelectron. 63 (2015), 218–231.
18. [18] Bazylińska, U., Skrzela, R., Piotrowski, M., Szczepanowicz, K., Warszyński, P., Wilk, K.A., Influence of dicephalic ionic surfactant interactions with oppositley charged polyelectrolyte upon in vitro release from oil core nanocapsules. Bioelectrochemisty 87 (2012), 147–153.
19. [19] Bazylińska, U., Zieliński, W., Kulbacka, J., Samoć, M., Wilk, K.A., New diamidequat-type surfactants in fabrication of long-sustained theranostic nanocapsules: colloidal stability, drug delivery and bioimaging. Colloid Surf. B: Biointerfaces, 2015, 10.1016/j.colsurfb.2015.06.043.
20. [20] Jędrych, E., Flis, S., Sofińska, K., Jastrzębski, Z., Chudy, M., Dybko, A., Brzoózka, Z., Evaluation of cytotoxic effect of 5-fluorouracil on human carcinoma cells in microfluidic system. Sens. Actuators B—Chem. 160 (2011), 1544–1551.
21. [21] Jastrzębska, E., Bułka, M., Rybicka, N., Żukowski, K., Analysis of the efficiency of photodynamic therapy using a microsystem for mono-, co- and mixed cultures. Sens. Actuators B—Chem. 221 (2015), 1356–1365.
22. [22] Bazylińska, U., Saczko, J., Nanoemulsion-templeted polyelectrolyte multifunctional nanocapsules for DNA entrapment and bioimaging. Colloid Surf. B: Biointerfaces, 2015, 10.1016/j.colsurfb.2015.07.056.
23. [23] Ernsting, M.J., Murakami, M., Roy, A., Li, S.D., Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles. J. Control. Release 172 (2013), 782–794.
24. [24] Gao, H., He, G., The interaction of nanoparticles with plasma proteins and the consequent influence on nanoparticles behavior. Expert Opin. Drug Deliv. 11 (2014), 409–420.
25. [25] Renno, R.Z., Terada, Y., Haddadin, M.J., Michaud, N.A., Gragoudas, E.S., Miller, J.W., Selective photodynamic therapy by targeted verteporfin delivery to experimental choroidal neovascularization mediated by a homing peptide to vascular endothelial growth factor receptor-2. Arch. Ophthalmol. 122 (2004), 1002–1011.
26. [26] Ammar, D.A., Kahook, M.Y., In vitro effects of verteporfin on ocular cells. Mol. Vis. 19 (2013), 424–429.
27. [27] Lui, H., Hobbs, L., Tope, W., Lee, P., Elmets, C., Provost, N., Chan, A., Neyndorff, H., Su, X., Jain, H., Hamzavi, I., McLean, D., Bissonnette, R., Photodynamic therapy of multiple nonmelanoma skin cancers with verteporfin and red light-emitting diodes: two-year results evaluating tumor response and cosmetic outcomes. Arch. Dermatol. 140 (2004), 26–32.
28. [28] Momma, T., Hamblin, M., Wu, H., Hasan, T., Photodynamic therapy of orthotopic prostate cancer with benzoporphyrin derivative: local control and distant metastasis. Cancer Res. 58 (1998), 5425–5431.
29. [29] Konan-Kouakou, Y.N., Boch, R., Gurny, R., Allémann, E., In vitro and in vivo activities of verteporfin-loaded nanoparticles. J. Control. Release 103 (2005), 83–91.
30. [30] Fateye, B., Wan, A., Yang, X., Myers, K., Chen, B., Comparison between endothelial and tumor cells in the response to verteporfin-photodynamic therapy and a PI3 K pathway inhibitor. Photodiag. Photodyn. Ther. 12 (2015), 19–26.
31. [31] Celli, J.P., Solban, N., Liang, A., Pereira, S.P., Hasan, T., Verteporfin-based photodynamic therapy overcomes gemcitabine insensitivity in a panel of pancreatic cancer cell lines. Lasers Surg. Med. 43 (2011), 565–574.
32. [32] Park, S., Hong, S.P., Oh, T.Y., Bang, S., Chung, J.B., Song, S.Y., Paclitaxel augments cytotoxic effect of photodynamic therapy using verteporfin in gastric and bile duct cancer cells. Photochem. Photobiol. Sci. 7 (2008), 769–774.
33. [33] Hu, Z., Rao, B., Chen, S., Duanmu, J., Targeting tissue factor on tumour cells and angiogenic vascular endothelial cells by factor VII-targeted verteporfin photodynamic therapy for breast cancer in vitro and in vivo in mice. BMC Cancer, 10, 2010, 235.
34. [34] Labow, R.S., Higginson, L.A., Irvine, J., Keaney, M., Masters, R.G., Marquis, J.F., Meek, E., Mussivand, T., Walley, V.M., Logan, P., et al. Assessment of the cytotoxicity of the photosensitizing drug BPD verteporfin using human vascular smooth muscle cells in culture. J. Cardiovasc. Pharmacol. 26 (1995), 728–736.
35. [35] Ziołkowska, K., Kwapiszewski, R., Brzózka, Z., Microfluidic devices as tools for mimicking the in vivo environment. New J. Chem. 35 (2011), 979–990.
36. 2 inorganic photosensitizers for NIR-triggered photodynamic therapy and enhanced chemotherapy in drug-resistant breast cancers. Biomaterials 57 (2015), 93–106.
37. [37] Deda, D.K., Uchoa, A.F., Caritá, E., Baptista, M.S., Toma, H.E., Araki, K., A new micro/nanoencapsulated porphyrin formulation for PDT treatment. Int. J. Pharm. 376 (2009), 76–83.
38. [38] Huh, D., Matthews, B.D., Mammoto, A., Montoya-Zavala, M., Hsin, H.Y., Ingber, D.E., Reconstituting organ-Level lung functions on a chip. Science 328 (2010), 1662–1668.